Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2020
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Jianming Xu, Jie Shen, Shanzhi Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
The Lancet. Oncology
|
November 27, 2025
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
Shukui Qin, Shanzhi Gu, Stephen L Chan, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
Lancet (London, England)
|
July 27, 2023
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Shukui Qin, Stephen L Chan, Shanzhi Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Herui Yao, Min Yan, Zhongsheng Tong, et al.
Liver Cancer
|
May 26, 2025
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study
Zhaolong Pan, Dongming Liu, Junbo Cao, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
Dan Liu, Chunguang Ma, Ping Lu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2025
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
Chunmei Bai, Yi Zheng, Meili Sun, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2020
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Jianming Xu, Jie Shen, Shanzhi Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
The Lancet. Oncology
|
November 27, 2025
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
Shukui Qin, Shanzhi Gu, Stephen L Chan, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
Lancet (London, England)
|
July 27, 2023
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Shukui Qin, Stephen L Chan, Shanzhi Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Herui Yao, Min Yan, Zhongsheng Tong, et al.
Liver Cancer
|
May 26, 2025
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study
Zhaolong Pan, Dongming Liu, Junbo Cao, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
Dan Liu, Chunguang Ma, Ping Lu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2025
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
Chunmei Bai, Yi Zheng, Meili Sun, et al.
Page
of 8